agilon health, inc.

Capital Position and Balance Sheet agilon health s balance sheet as of June 30, 2025 included cash and cash equivalents and marketable securities of $327 million and total debt of $35 million.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Fair Value Measurements The Company s financial instruments consist of cash and cash equivalents, restricted cash and equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which consist of a term loan and a revolving credit facility.

SEC original ↗agilon health, inc. — 10-Q Quarterly report10-QAug 5, 2026

The fair values of the term loan and revolving credit facility approximate the carrying values because the interest rates on such borrowings approximate market rates as of the reporting date.

SEC original ↗agilon health, inc. — 10-Q Quarterly report10-QAug 5, 2026

Such borrowings are classified within Level 2 of the fair 14 Table of Contents value hierarchy.

SEC original ↗agilon health, inc. — 10-Q Quarterly report10-QAug 5, 2026

Debt On February 18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021, the Second Amendment to Credit Agreement, dated as of May 25, 2023, the Third Amendment to Credit Agreement, dated as of February 12, 2026 (the Third Amendment ), and the Fourth Amendment to Credit Agreement, dated as of April 9, 2026, the Credit Agreement ), which includes: (i) a secured term loan facility (the Secured Term Loan Facility ) and (ii) a senior secured revolving credit facility (the Secured Revolving Facility, and together with the Secured Term Loan Facility, the Credit Facility ).

SEC original ↗agilon health, inc. — 10-Q Quarterly report10-QAug 5, 2026

As of June 30, 2026, the Company had $ 31.5 million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $ 20.8 million, as the Company had outstanding letters of credit totaling $ 69.2 million.

SEC original ↗agilon health, inc. — 10-Q Quarterly report10-QAug 5, 2026

htm EX-99.1 Document Exhibit 99.1 agilon health Reports Second Quarter 2025 Results Total revenues of $1.4 billion in the second quarter 2025 Medicare Advantage membership of 498,000, and total members on the agilon platform of 614,000 as of June 30, 2025 Continued execution on strategic initiatives to enhance financial and clinical data visibility, operational discipline and partnership performance agilon suspends its full year 2025 earnings guidance due to leadership change, ongoing implementation of performance visibility initiatives as well as dynamic market conditions Westerville, O.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

with a proven ability to serve as the long-term solution for practices focused on outcomes, said Ronald A.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

We have continued advancing strategic initiatives in 2025 to improve performance including enhancing our platform, data visibility, quality and delivery programs and contract economics that we expect to fully realize the benefit of next year given the nature of our business cycle.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Suspends 2025 Guidance and Assumptions In conjunction with the announcement of agilon s leadership change and the evaluation of additional actions to optimize operating performance, as well as continued execution of ongoing initiatives and market uncertainty which may impact future results, agilon is suspending its previously issued full-year 2025 financial guidance and related assumptions.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

agilon provides the technology, people, capital, process, and access to a peer network of 2,200+ primary care physicians (PCPs) that allow its physician partners to maintain their independence and focus on the total health of their most vulnerable patients.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Nevertheless, as we progressed through this transition year, it s become clear that the industry headwinds are more acute than previously expected, and our enhanced data platform is providing visibility that indicates our 2024 and 2025 risk adjustment is also lower than previously expected, which is impacting near-term results.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Suspends 2025 Guidance and Assumptions In conjunction with the announcement of agilon s leadership change and the evaluation of additional actions to optimize operating performance, as well as continued execution of ongoing initiatives and market uncertainty which may impact future results, agilon is suspending its previously issued full-year 2025 financial guidance and related assumptions.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be outside our control.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Additionally, the suspension of our previously issued full-year 2025 financial guidance, ongoing implementation of performance initiatives, leadership changes, and dynamic market conditions create additional uncertainty regarding our future operating and financial performance.

SEC original ↗agilon health, inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

These risks and uncertainties that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, but are not limited to, those factors discussed in our filings with the Securities and Exchange Commission (the SEC ), including the factors discussed under Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which can be found at the SEC s website at www.

SEC original ↗agilon health, inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025